N.E.W. Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

N.E.W. Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90.9K	Hold	1,667	–	–	0.01%	303
2026 Q1	$79.3K	Hold	1,667	–	–	0.01%	310
2025 Q4	$87.4K	Sell	1,667 -407	-20%	-$24.4K	0.01%	296
2025 Q3	$134K	Buy	2,074 +680	+49%	+$39K	0.01%	223
2025 Q2	$67.8K	Buy	+1,394	New	+$53.9K	0.01%	277

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

N.E.W. Advisory Services's CRSP Position: Q2 2026 in Review

N.E.W. Advisory Services held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1,667 shares worth $90.9K. The position accounts for 0.01% of the portfolio, ranked #303.

N.E.W. Advisory Services first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $134K in Q3 2025. 303 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

N.E.W. Advisory Services held 1,667 shares of CRISPR Therapeutics worth $90.9K as of Q2 2026.
N.E.W. Advisory Services left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.01% of N.E.W. Advisory Services's portfolio in Q2 2026, its #303 holding.
N.E.W. Advisory Services first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
N.E.W. Advisory Services's CRISPR Therapeutics position peaked at $134K in Q3 2025.
303 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on N.E.W. Advisory Services's 13F filing for Q2 2026, filed 6 Aug 2026.